1620 Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

1620 Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-447	Closed	-$24.2K	–	652
2025 Q3	$24.2K	Sell	447 -56	-11%	-$3.2K	0.02%	366
2025 Q2	$27.6K	Sell	503 -925	-65%	-$54.5K	0.02%	366
2025 Q1	$101K	Sell	1,428 -6	-0.4%	-$404	0.08%	213
2024 Q4	$94.3K	Buy	1,434 +86	+6%	+$5.76K	0.07%	228
2024 Q3	$94.8K	Buy	1,348 +25	+2%	+$2.09K	0.07%	238
2024 Q2	$109K	Buy	+1,323	New	+$110K	0.08%	206

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

1620 Investment Advisors's BMRN Position: Q4 2025 in Review

1620 Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 447 shares — an estimated $24.2K sold.

1620 Investment Advisors first reported a position in BMRN in Q2 2024 and held it in 6 quarters. The position peaked at $109K in Q2 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

1620 Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
1620 Investment Advisors sold 447 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $24.2K.
1620 Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 6 quarters.
1620 Investment Advisors's BioMarin Pharmaceuticals position peaked at $109K in Q2 2024.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on 1620 Investment Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.